Maurer, HH; Kraemer, T; Springer, D; Staack, RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (Ecstasy), piperazine, and pyrrolidinophenone types. A synopsis. Ther. Drug Monit., 1 Apr 2004, 26 (2), 127–131. 121 kB.
Westphal, F; Junge, T; Rõsner, P; Fritschi, G; Kleinc, B; Girreser, U. Mass spectral and NMR spectral data of two new designer drugs with an α-aminophenone structure: 4′-Methyl-α-pyrrolidinohexanophenone and 4′-methyl-α-pyrrolidinobutyrophenone. Forensic Sci. Int., 1 Jan 2007, 169 (1), 32–42. 1.5 MB. https://doi.org/10.1016/j.forsciint.2006.07.024
Sauer, C; Hoffmann, K; Schimmel, U; Peters, FT. Acute poisoning involving the pyrrolidinophenone-type designer drug 4′-methyl-alpha-pyrrolidinohexanophenone (MPHP). Forensic Sci. Int., 20 May 2011, 208 (1–3), e20–e25. 455 kB. https://doi.org/10.1016/j.forsciint.2011.02.026
EMCDDA. New drugs in Europe, 2012, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2013. 773 kB. #36
Fornal, E. Study of collision-induced dissociation of electrospray-generated protonated cathinones. Drug Test. Analysis, 1 Jul 2014, 6 (7-8), 705-715. 527 kB. https://doi.org/10.1002/dta.1573 #26
Sasaki, R; Kato, M; Matsumoto, T; Udagawa, A; Matsuzaki, R. A method for identifying designer drugs of synthetic cathinones. JCCL, 1 Dec 2015, (55), 17–41. 663 kB. #23 Japanese, English abstract MS,NMR,IR,UV